There are lots of growth opportunities and new regulatory initiatives for devices in India, affirms a report by o3 Capital Global Advisory Private Limited, an Indian investment banking firm. But device-related issues are not high on the agenda of FDA Commissioner Hamburg during her trip to the country concluding Feb. 18.

While the overall Indian pharmaceutical market is seeing early signs of a rebound after a dull 2013, interest is steadily building for buyout targets like high yield brands, medical devices and companies that bring expertise to manufacturing.

While the overall Indian pharmaceutical market is seeing early signs of a rebound after a dull 2013, interest is steadily building for buyout targets like high yield brands, medical devices and companies that bring expertise to manufacturing.